DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Clinical trial NCT03716180 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03716180
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-05
- Primary completion
- 2020-10-08
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.